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 Abstract: We present a patient with intractable neuro-
pathic pain because of radiation-induced transverse myelitis
unresponsive to medical treatment. After a successful trial
of spinal cord stimulation, a permanent stimulator was
implanted. Improvement was noted in verbal pain score,
medication usage and function. Spinal cord stimulation may
offer a therapeutic option for patients with neuropathic pain
resulting from transverse myelitis and should be considered
when other treatments fail. 
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CASE REPORT
A 54-year-old right-handed man with a 30 pack-year
history of smoking was diagnosed with right lower lobe
nonsmall cell lung carcinoma, which was treated with
chemotherapy (paclitaxel and carboplatin) followed by
resection and radiation. He received a total of 5040 cGy
in 28 fractions. Two months following the completion
of radiation therapy, he developed gradual onset of
severe dysesthesia in the left leg, evolving into a circum-
ferential pattern, extending from the hip and buttock
down to the toes. He developed burning, pins and
needle sensation, accompanied by severe tactile hyper-
sensitivity. The pain increased with physical activity,
impacting his ability to ambulate. It worsened during
the night and prevented adequate sleep. The only alle-
viating factor was immobilization of the legs in an
elevated position. Mild weakness of the legs and mild
bladder dysfunction were also noted. The reported
verbal pain score at the first interview was 10/10.
On examination, a sensory level was detected at T5.
Decreased sensation to pin prick on the left leg and
decreased vibration on the right leg were identified.
Nerve conduction studies of the lower extremities
remained unremarkable. Magnetic resonance imaging of
the spinal cord revealed increased signal intensity on
T2-weighted images extending from the second thoracic
vertebral level through the fourth thoracic vertebral level,
consistent with transverse myelitis with diffuse homoge-
neous increased signal intensity within the vertebrae.
The patient’s employment as a real estate agent was
jeopardized. He met diagnostic criteria for major
depression. Initial treatment consisted of gabapentin,
which was escalated to 900 mg three times a day.
Nortriptyline was added and titrated up to 100 mg at
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bedtime. Pain scores did not improve on this regimen.
Transdermal fentanyl was instituted at a dose of 25 mg/
hour every 72 hours and increased gradually to 75 mg/
hours every 72 hours. Morphine IR 15 mg every
4 hours PRN was provided for breakthrough pain.
Acetaminophen 500 mg and ibuprofen 400 mg every
6 hours was continued. The patient reported minimal
relief of pain, accompanied by fatigue, drowsiness, and
dizziness. At a later time, topiramate 100 mg a day was
started. For depression, he was prescribed paroxetine
40 mg a day. He continued of complain of pain rated
at 9–10/10; depression, function, and quality of life
deteriorated.
Transdermal fentanyl was changed to methadone and
the dose increased gradually to 40 mg per day. Despite
this regimen, there was minimal relief. After 8 months of
conservative treatment, a spinal cord stimulator trial was
carried out. A single quad electrode array (Medtronic
Inc., Minneapolis, MN, U.S.A.) was placed, with the
uppermost electrode positioned at the top of the T10
vertebral body as viewed on AP Fluoroscopy. Corre-
sponding paresthesias were achieved in both legs
with “electrode 0 off,” “electrode 1–,” “electrode 2+,”
“electrode 3 off.” The trial continued for 5 days, during
which the patient had almost complete resolution of pain
and was able to discontinue the use of breakthrough
medication. Three weeks after the initial trial, the patient
underwent permanent implantation. Placement of a flat
electrode (Specify lead, Medtronic) at the level of T10
was performed through a thoracic laminotomy.
The patient experienced dramatic pain relief. Metha-
done and paroxetine were decreased and all other medi-
cations were discontinued. He has been followed for
18 months after permanent implantation and continues
to rate his pain at 0–1/10 with the stimulator on. When
the stimulator is off, pain intensity increases to 5–6/10
but remains tolerable with the use of methadone 15 mg
per day. His depression has improved significantly and
he returned to work.
DISCUSSION
Transverse myelitis is a rare inflammatory disease of the
spinal cord, which has an incidence of 0.46 per 100 000
in the United States.1 Two-thirds of acute transverse
myelitis episodes are idiopathic. Viral infections appear
to trigger one-third of the cases in adults and at least
half the cases in children.2 Radiation-induced transverse
myelitis occurs more rarely.3 Yamada et al. surveyed 409
patients whose spinal cords were irradiated with more
than 30 Gy to study the relationship between the dose of
spinal irradiation and the incidence of radiation myeli-
tis.3 Radiation myelitis was observed in 26 cases includ-
ing 3 patients who developed transverse myelitis.3 The
calculated 5-year incidence of transverse myelitis was
approximately 0% at 40 Gy, 5% at 50 Gy, 10% at
60 Gy and 20% at 70 Gy.3 Current data indicate that
given in once-daily fractions of less than 200 cGy, the
risk of delayed radiation myelopathy is less than 0.5%
for a total dose of 4500 cGy and 5% for total doses of
5700 cGy to 6100 cGy.4
Pain or dysesthesia is usually the most debilitating
sequela of transverse myelitis, occurring in as many as
40% of patients with this disorder.5 Treatment can
consist of antiepileptic medication along with antide-
pressants. Opioids have little to offer patients with
transverse myelitis, as was evident in this case, especially
in the presence of side effects like constipation and
urinary retention.5 Overuse of opioid medication in the
absence of identifiable improvement in pain relief and/or
function should be avoided. When traditional means of
treating neuropathic pain fail to offer tangible benefit,
interventional modalities may need to be considered.6 It
is unknown if the pain in patients with transverse myeli-
tis is sympathetically maintained. No literature is avail-
able regarding the role of sympathetic blocks in this
entity. Although this was not tried in this patient, it is
not unreasonable to attempt this minimally invasive
option before proceeding to spinal cord stimulation.
Spinal stimulation was first described by Shealy after
work completed in the 1960s with electrodes placed
epidurally over the dorsal columns of the spinal cord.7
Further refinement of the device led to the use of totally
implantable generator and electrode systems, allowing
for adjustment of stimulation parameters and optimiza-
tion of pain relief. Over the last three decades, multiple
studies have demonstrated the safety and efficacy of
spinal stimulation for the treatment of chronic pain.6
Spinal stimulation has been used with varying degrees
of success in the treatment of neuropathic pain
syndromes including radiculopathy, peripheral nerve
injury, postherpetic neuralgia, diabetic neuropathy, and
chemotherapy-induced neuropathy.6 Spinal stimulation
has also been utilized for failed back surgery syndrome,
complex regional pain syndrome, peripheral vascular
disease, and angina pectoris.6
Despite the neuropathic nature of pain occurring in
patients with transverse myelitis, a review of the litera-
ture provides limited information on the use of spinal
cord stimulation in this condition.8–10 Dooley et al. and
Tani et al. documented a variable degree of success with
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the use of spinal stimulation for patients with transverse
myelitis.9,10 Laffey et al. described one case involving a
patient with idiopathic transverse myelitis in which
spinal cord stimulation provided marked improvement
in quality of life with a 70% reduction in pain
12 months post implant.8
Selection of patients for permanent spinal cord
implantation can be challenging. Clinical predictors of
outcome are still under study and additional data are
needed to allow for more accurate prediction of
outcome.11–13 Decisions regarding patient selection,
choice of lead (percutaneous vs. surgical), and generator
(single use vs. rechargeable) need to be considered care-
fully. Surgical leads have demonstrated longer survival
time in some series and “Specify leads” (Medtronic)
have been reported to provide better axial coverage than
percutaneous leads.11,14 Somatosensory evoked poten-
tials have been studied to assist in predicting outcome
from spinal stimulation.15 Pain because of lesions
located proximal to the dorsal root ganglion should
demonstrate normal central conduction time if spinal
cord stimulation is being considered. As an alternative,
when trial stimulation is possible with a percutaneous
lead, as in our case, Sindou et al. conclude that use of a
percutaneous trial can serve as a first step before defini-
tive implantation is performed.15
Although spinal cord stimulation in central neuro-
pathic pain syndromes has shown inconsistent results,
our case demonstrates the potential beneficial effect of
spinal cord stimulation in the treatment of neuropathic
pain resistant to conventional treatment resulting from
radiation-induced transverse myelitis.8 Further study is
required to delineate subsets of central pain that may
respond to this treatment modality.
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